Program(s) for ALS
Amyotrophic Lateral Sclerosis
Key Facts
About AviadoBio
AviadoBio is a private, clinical-stage biotech pioneering gene therapies for neurodegenerative diseases, with its lead program AVB-101 in Phase 1/2 trials for frontotemporal dementia (FTD-GRN). The company's strategy is built on a deep understanding of neuroanatomy and a suite of proprietary platforms, including the vMiX™ RNA silencing platform, designed to overcome the critical delivery challenges in treating neurological disorders. Founded on research from King's College London and the UK Dementia Research Institute, AviadoBio is backed by a strong syndicate of life science investors and is led by an experienced team, including CEO Lisa Deschamps. The company is pre-revenue and is advancing a pipeline that also targets retinitis pigmentosa, Alzheimer's/tauopathies, and ALS.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Cell Therapy for ALS | INCELL | Unknown |
| ALS Research | GliaPharm | Research |
| ALS Disease Model Service | NeuroProof | Pre-clinical |
| ALS Biomarker Program | Linus Biotechnology | Pre-clinical |
| ALS Research (post-RADICAVA) | Tanabe Pharma America | Preclinical/Research |
| ALS Program | Biorchestra | Preclinical |
| TCD601 for ALS | ITB Med | Phase 2 |
| ILB® for ALS | TikoMed | Phase 2 |
| ALS Patient-Led Research Initiative | BGI | Research |
| ALS Pathway Discovery | Anima Biotech | Preclinical |
| Pridopidine | Prilenia Therapeutics | Phase 3 |
| Foralumab (intranasal) | Tiziana Life Sciences | Phase 2 |